A biotech executive and scientific innovator with over 15 years of experience translating immuno-oncology discoveries into clinically actionable therapies. Dr. Greta Garrido has contributed to two FDA approvals, advanced multiple IND-enabling programs, and built therapeutic platforms spanning RNA oligonucleotides, engineered T-cell therapies, neoantigen discovery, and antibody technologies. Known for bridging deep scientific insight with strategic execution, she leads platform development, translational strategy, biomarker innovation, and early clinical readiness across diverse therapeutic modalities. As CEO & Co-Founder of Sebastian BioPharma, she is advancing a first-in-class dual payload AOC platform integrating modular assembly, multi-payload co-delivery, and broad tissue reach - unmatched by current clinical platforms. Career at-a-glance: Gritstone Bio  Nurix Therapeutics  BlueSphere Bio  University of Miami